Clinical Trial of Reconstruction After Proximal Gastrectomy

Sponsor
Oncogastroenterology Committee of Chinese (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05418920
Collaborator
Tang-Du Hospital (Other), First Affiliated Hospital Xi'an Jiaotong University (Other), General Hospital of Ningxia Medical University (Other), Henan Provincial People's Hospital (Other), The First Affiliated Hospital of Shanxi Medical University (Other)
250
2
60

Study Details

Study Description

Brief Summary

  1. To explore a simple, safe, post-proximal gastrectomy reconstruction method with good absorption and digestive function in order to improve patients' postoperative quality of life; 2) To fill the gap in the comparison of clinical efficacy between left-open single-flap technique and double-flap technique in this specialized field in China; 3) To utilize the experience and foundation of gastrointestinal surgery in the treatment of gastric cancer and integrate the advantageous resources in China; 4) To establish a large-sample, multicenter randomized clinical study in order to promote the establishment and improvement of relevant norms of gastrointestinal reconstruction
Condition or Disease Intervention/Treatment Phase
  • Procedure: left-opening single-flap technique
  • Procedure: double-flap group technique
N/A

Detailed Description

Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer-related deaths each year. Although the incidence of gastric cancer has decreased worldwide compared to the past, the incidence of esophagogastric junction cancer and upper 1/3 gastric cancer is gradually increasing. Currently, the main treatment for esophagogastric junction cancer and upper gastric cancer is surgery. However, there is no clinical consensus on the choice of surgical approach for these patients. Compared with total gastrectomy, proximal gastrectomy can preserve the physiological function of the stomach and has great advantages in nutrient absorption, thus it has been widely accepted in Asian countries.

However, the risk of developing reflux esophagitis after proximal gastrectomy is high, which seriously affects patients' postoperative quality of life. In order to reduce the occurrence of postoperative complications, clinicians continue to improve the methods of GI reconstruction. Currently, the common methods of GI reconstruction after proximal gastrectomy include esophagogastrostomy (EG), jejunal intubation (JI), jejunal pouch intubation (JPI), and dual-tract reconstruction (DTR). However, the choice of the optimal reconstruction method after proximal gastrectomy remains controversial, and there is no standard approach to GI reconstruction. In 2016, Kuroda et al. reported a new surgical approach with a double-flap technique after proximal gastrectomy and showed satisfactory short-term outcomes compared with conventional esophagogastric anastomosis. At the 1-year postoperative follow-up, no reflux esophagitis was detected in all patients. At the same time, the rate of anastomotic stenosis was noteworthy.

This study will be the first attempt at a left-open single-flap technique, which was modified from the double-flap technique. The short-term outcome was satisfactory in all patients. This study will establish a large sample, multicenter randomized clinical study. By exploring a simple, safe, good absorption and digestive function method of post-proximal gastrectomy reconstruction to improve patients' postoperative quality of life and fill the gap in the comparison of clinical efficacy between left-open single-flap technique and double-flap technique in this specialized field. This will promote the establishment and improvement of the specifications related to gastrointestinal reconstruction.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparing the Efficacy of Double-flap Technique Versus Single-flap Technique After Proximal Gastrectomy: a Multicentre Randomized Controlled Trial
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Jul 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: the trial group (left-opening single-flap group)

left-opening single-flap group

Procedure: left-opening single-flap technique
left-opening single-flap technique

Active Comparator: the control group (double-flap group)

double-flap group

Procedure: double-flap group technique
double-flap group technique

Outcome Measures

Primary Outcome Measures

  1. Incidence of reflux esophagitis [12 months]

    Incidence of reflux esophagitis

Secondary Outcome Measures

  1. Overall postoperative complication rate [30 days]

    Overall postoperative complication rate

  2. Incidence of anastomotic fistula [30 days]

    Incidence of anastomotic fistula

  3. Operation time [intraoperative]

    Operation time

  4. Bleeding loss volume [intraoperative]

    Bleeding loss volume

  5. incidence of anastomotic stricture [30 days]

    incidence of anastomotic stricture

  6. Incidence of reflux esophagitis [6 days]

    Incidence of reflux esophagitis

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  1. Patients aged 18-80 years, regardless of gender;

  2. Siewert III of the esophagogastric junction adenocarcinoma: Stage Ⅰ(cT1-2N0M0) or adenocarcinoma of the upper part of the stomach: Stage Ⅰ(cT1-2N0M0), Stage II( cT1-2N1-3M0 / cT3-4N0M0), Stage III(cT3-4aN1-3M0); patients who are suitable for surgery according to the 8th AJCC clinical staging of gastric cancer;

  3. Primary lesion diagnosed by preoperative endoscopic end pathology: tumor diameter <4 cm and located in the upper part of the stomach (including the esophagogastric junction), histologically confirmed adenocarcinoma;

  4. Preoperative ASA score: I, II, or III;

  5. Preoperative Karnofsky physical status score: ≥ 70%; or preoperative ECOG physical status score: ≤ 2;

  6. No distant metastases (confirmed by preoperative chest X-ray, abdominal ultrasound, and upper abdominal CT); no peritoneal implant metastases (confirmed by laparoscopic exploration surgery);

  7. R0 surgical outcome is expected to be obtained with radical gastrectomy of D2 proximal gastric cancer;

  8. Patients and their families voluntarily participate in this study and sign the informed consent form after understanding the study content.

Exclusion Criteria

  1. Patients received any preoperative treatment, such as chemotherapy, radiotherapy, targeted therapy or immunotherapy; preoperative neoadjuvant chemotherapy recipients;

  2. Patients with clinical stage exceeding Siewert III of the esophagogastric junction adenocarcinoma: Stage Ⅰ(cT1-2N0M0) or more than adenocarcinoma of the upper part of the stomach: Stage Ⅰ(cT1-2N0M0), Stage II(cT1-2N1-3M0/cT3-4N0M0), Stage III(cT3-4aN1-3M0);

  3. Patients with acute infections, especially biliary tract infections;

  4. Patients with complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery;

  5. Patients with uncorrectable coagulation dysfunction;

  6. Patients with vital organ failure, such as heart, lung, liver, brain, kidney, etc.

  7. Severe central nervous system disease, mental disorders, or impaired consciousness;

  8. Pregnant or lactating women;

  9. Patients with distant metastases;

  10. Patients with a primary tumor at another site diagnosed within the past 5 years;

  11. Preoperative ASA score: ≥ IV;

  12. Preoperative ECOG physical status score: ≥ 2;

  13. History of continuous systemic corticosteroid therapy within the past 1 month;

  14. History of unstable angina, myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months;

  15. Patients with concurrent surgical treatment of other diseases;

  16. Patients with immunodeficiency, immunosuppression, or autoimmune diseases (organ transplant requiring immunosuppressive therapy within the past 5 years, allogeneic bone marrow transplant patients, taking immunosuppressive drugs, etc.);

  17. Patients with concurrent participation in other clinical studies;

  18. Patients refusing to sign an informed consent form to participate in this study;

  19. Preoperative imaging: regional fusion of enlarged lymph nodes (maximal diameter > 3 cm).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Oncogastroenterology Committee of Chinese
  • Tang-Du Hospital
  • First Affiliated Hospital Xi'an Jiaotong University
  • General Hospital of Ningxia Medical University
  • Henan Provincial People's Hospital
  • The First Affiliated Hospital of Shanxi Medical University

Investigators

  • Study Chair: Nan Wang, MD, Tang-Du Hospital
  • Study Chair: Chao Zhang, MD, Henan Provincial People's Hospital
  • Study Chair: Lei Wang, MD, General Hospital of Ningxia Medical University
  • Study Chair: Renwei Chang, MD, The First Affiliated Hospital of Shanxi Medical University
  • Study Chair: Junjun She, MD, First Affiliated Hospital Xi'an Jiaotong University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Oncogastroenterology Committee of Chinese
ClinicalTrials.gov Identifier:
NCT05418920
Other Study ID Numbers:
  • single-flap technique
First Posted:
Jun 14, 2022
Last Update Posted:
Jul 5, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Oncogastroenterology Committee of Chinese
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2022